Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Rallybio Corporation - Common Stock (NQ:RLYB)

0.2525 -0.0075 (-2.88%)
Streaming Delayed Price Updated: 1:48 PM EDT, Apr 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 118,690
Open 0.2500
Bid (Size) 0.2519 (7)
Ask (Size) 0.2598 (7)
Prev. Close 0.2600
Today's Range 0.2500 - 0.2656
52wk Range 0.2201 - 2.010
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
This General Motors Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Via Benzinga
Which stocks have an unusual volume on Monday?
Unusual volume stocks are being observed in Monday's session. 
Via Chartmill

Performance

YTD
-73.4%
-73.4%
1 Month
-60.7%
-60.7%
3 Month
-71.6%
-71.6%
6 Month
-76.8%
-76.8%
1 Year
-86.2%
-86.2%

More News

Read More
This PTC Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints
Via Benzinga
Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT
From Rallybio Corporation
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
From Rallybio Corporation
Via Business Wire
Rallybio to Present at the TD Cowen 45th Annual Health Care Conference
From Rallybio Corporation
Via Business Wire
Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial
From Rallybio Corporation
Via Business Wire
Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025
From Rallybio Corporation
Via Business Wire
Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting
From Rallybio Corporation
Via Business Wire
Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025
From Rallybio Corporation
Via Business Wire
Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women
From Rallybio Corporation
Via Business Wire
Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference
From Rallybio Corporation
Via Business Wire
Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor
From Rallybio Corporation
Via Business Wire
Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212
From Rallybio Corporation
Via Business Wire
Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates
From Rallybio Corporation
Via Business Wire
Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT
From Rallybio Corporation
Via Business Wire
Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting
From Rallybio Corporation
Via Business Wire
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting
From Rallybio Corporation
Via Business Wire
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit
From Rallybio Corporation
Via Business Wire
Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree
From Rallybio Corporation
Via Business Wire
Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis
From Rallybio Corporation
Via Business Wire
Rallybio to Present at Upcoming Investor Conferences
From Rallybio Corporation
Via Business Wire

Frequently Asked Questions

Is Rallybio Corporation - Common Stock publicly traded?
Yes, Rallybio Corporation - Common Stock is publicly traded.
What exchange does Rallybio Corporation - Common Stock trade on?
Rallybio Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Rallybio Corporation - Common Stock?
The ticker symbol for Rallybio Corporation - Common Stock is RLYB on the Nasdaq Stock Market
What is the current price of Rallybio Corporation - Common Stock?
The current price of Rallybio Corporation - Common Stock is 0.2525
When was Rallybio Corporation - Common Stock last traded?
The last trade of Rallybio Corporation - Common Stock was at 04/16/25 01:48 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.